Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Current Assets (2019 - 2025)

Keros Therapeutics filings provide 7 years of Current Assets readings, the most recent being $315.4 million for Q4 2025.

  • On a quarterly basis, Current Assets fell 46.44% to $315.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $315.4 million, a 46.44% decrease, with the full-year FY2025 number at $315.4 million, down 46.44% from a year prior.
  • Current Assets hit $315.4 million in Q4 2025 for Keros Therapeutics, down from $719.3 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $759.5 million in Q1 2025 to a low of $222.4 million in Q2 2022.
  • Median Current Assets over the past 5 years was $324.9 million (2023), compared with a mean of $393.6 million.
  • Biggest five-year swings in Current Assets: soared 337.28% in 2021 and later plummeted 46.44% in 2025.
  • Keros Therapeutics' Current Assets stood at $251.4 million in 2021, then rose by 13.65% to $285.8 million in 2022, then rose by 21.53% to $347.3 million in 2023, then surged by 69.57% to $588.9 million in 2024, then plummeted by 46.44% to $315.4 million in 2025.
  • The last three reported values for Current Assets were $315.4 million (Q4 2025), $719.3 million (Q3 2025), and $732.8 million (Q2 2025) per Business Quant data.